<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi> pharmacokinetic parameters in adolescent patients with renal compromise are not available from the medical literature </plain></SENT>
<SENT sid="1" pm="."><plain>We describe a 14-year-old with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> treated with subcutaneous 5-<z:chebi fb="0" ids="2038">azacitidine</z:chebi> for disease relapse 2 years after hematopoietic stem cell transplant </plain></SENT>
<SENT sid="2" pm="."><plain>Because of renal compromise, <z:hpo ids='HP_0004395'>malnutrition</z:hpo>, and poor functional status, pharmacokinetic parameters were projected from existing literature data to select the patient's first <z:chebi fb="0" ids="2038">azacitidine</z:chebi> treatment course (1.5 mg/kg/d for 7 d) </plain></SENT>
<SENT sid="3" pm="."><plain>Posttreatment <z:chebi fb="0" ids="2038">azacitidine</z:chebi> plasma concentrations used to calculate patient-specific pharmacokinetic parameters corroborated initial estimates and systemic exposure associated with therapeutic benefit in adults and permitted individualization of treatment </plain></SENT>
</text></document>